超越STEMI范式:微轴流泵在心源性休克中应用范围的拓展
本研究回顾性分析11个中心2010至2023年976例接受微轴流泵(mAFP)治疗的心源性休克(CS)患者,其中AMI-CS占64.0%,Non-AMI-CS占36.0%。倾向性评分匹配后(n=444),两组180天死亡率相当(32.9% vs 33.3%;HR 0.89 [95%CI 0.65-1.21];p=0.46),但Non-AMI-CS组左室射血分数改善更显著(+17.8±17.0% vs +11.2±14.5%;p<0.001)。结论认为缺血与非缺血性CS在mAFP支持下长期结局等效,患者选择应基于休克严重程度和血流动力学表型而非单纯病因。
要点
- 匹配后AMI-CS与Non-AMI-CS的180天死亡率无显著差异(32.9% vs 33.3%;HR 0.89 [95%CI 0.65-1.21];p=0.46)。
- Non-AMI-CS患者心肌恢复更明显,LVEF改善幅度更大(+17.8±17.0% vs +11.2±14.5%;p<0.001)。
- 两组死亡独立预测因素包括年龄(每增加5岁)、SCAI E期、乳酸≥6 mmol/L、去甲肾上腺素使用及肾脏替代治疗。
核心结论
- 在真实世界大样本中,缺血性与非缺血性心源性休克接受mAFP支持的长期结局等效。
- 患者选择应依据休克严重程度和血流动力学表型,而非仅凭病因,支持更广泛评估mAFP的应用。
研究设计与样本
- 多中心回顾性分析,纳入11个高容量中心2010至2023年接受mAFP(Impella CP和5+[5.0和5.5])治疗的CS患者976例。
- 采用倾向性评分匹配(n=444)平衡基线差异,主要结局为180天全因死亡率,并用多因素logistic回归识别独立预测因素。
主要发现
- 队列中AMI-CS占64.0%,Non-AMI-CS占36.0%。
- 2010至2023年,两组180天死亡率均显著下降(AMI-CS Ptrend=0.01;Non-AMI-CS Ptrend=0.03)。
- 匹配后180天死亡率AMI-CS vs Non-AMI-CS为32.9% vs 33.3%(HR 0.89 [95%CI 0.65-1.21];p=0.46)。
- 心脏移植率(5.0% vs 9.0%;p=0.08)与持久LVAD植入率(10.8% vs 9.0%;p=0.77)相似。
- Non-AMI-CS组LVEF改善更大(+17.8±17.0% vs +11.2±14.5%;p<0.001)。
关键数值与推荐
- 主要结局:180天全因死亡率,匹配后两组无显著差异(HR 0.89 [95%CI 0.65-1.21];p=0.46)。
- 死亡独立预测因素:年龄(每5岁增加)、SCAI E期、乳酸≥6 mmol/L、去甲肾上腺素使用、肾脏替代治疗。
- 心肌恢复指标:Non-AMI-CS组LVEF改善+17.8±17.0%,AMI-CS组+11.2±14.5%(p<0.001)。
临床怎么用
- 对Non-AMI-CS患者可考虑使用mAFP支持,其180天生存与AMI-CS相当。
- 选择mAFP患者时应依据休克严重程度(如SCAI分期、乳酸水平)和血流动力学表型,而非仅凭病因。
- Non-AMI-CS患者接受mAFP支持后心肌恢复潜力更大,LVEF改善更显著。
局限性
- 回顾性研究设计,存在未测量混杂可能。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Microaxial flow pumps (mAFP) are increasingly used to treat cardiogenic shock (CS), but most evidence comes from acute myocardial infarction-related CS (AMI-CS). It remains unclear whether patients with non-ischemic CS (Non-AMI-CS) derive comparable benefits from mAFP support. This study aimed to compare clinical profiles, management strategies, and outcomes between AMI-CS and Non-AMI-CS patients treated with mAFP. METHODS: We retrospectively analyzed CS patients managed with mAFP (Impella CP and 5 + [5.0 and 5.5]) across 11 high-volume centers between 2010 and 2023. Propensity score matching was performed to account for baseline differences. The primary outcome was all-cause mortality at 180 days. Independent predictors of mortality were identified using multivariable logistic regression analysis. RESULTS: A total of 976 patients were included (64.0% AMI-CS; 36.0% Non-AMI-CS). From 2010 to 2023, 180-day mortality significantly declined in both groups (Ptrend = 0.01 for AMI-CS and 0.03 for Non-AMI-CS). After propensity score matching (n = 444), 180-day mortality was comparable between AMI-CS and Non-AMI-CS patients (32.9% vs 33.3%; HR 0.89 [95% CI, 0.65-1.21]; p = 0.46). Rates of heart transplantation (5.0% vs 9.0%; p = 0.08) and durable LVAD implantation (10.8% vs 9.0%; p = 0.77) were also similar. These findings were consistent across all prespecified subgroups and at 10-year follow-up. Independent predictors of mortality in both groups included age (per 5-year increase), SCAI stage E, lactate ≥6 mmol/L), norepinephrine use, and renal replacement therapy. Despite similar survival, Non-AMI-CS patients demonstrated greater myocardial recovery, with larger LVEF improvement (+17.8 ± 17.0% vs +11.2 ± 14.5%; p < 0.001). CONCLUSIONS: In this large, real-world cohort, ischemic and non-ischemic CS showed equivalent long-term outcomes under mAFP support. These findings suggest that patient selection should be guided by shock severity and hemodynamic phenotype rather than etiology alone, supporting broader evaluation of mAFP use.
引用
- Ughetto A, Schrage B, Fürholz M, et al. Beyond the STEMI paradigm: Expanding the scope of microAxial flow pump in cardiogenic shock. J Heart Lung Transplant. 2026. PMID: 41966345. doi:10.1016/j.healun.2026.03.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。